Drug Trial Radar · NCT05723770
Effects of NOV03 on the Tear Film
Last checked: Nov 20, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Aug 14, 2023
Primary completion
Dec 23, 2023
Study completion Dec 23, 2023
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
Conditions
- Dry Eye Disease (DED)
Interventions
instillation of NOV03Drug
This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thickness of the Mucus-aqueous Tear Film LayerTime frame: over 4 hours following instillation of NOV03
- Thinning Rate of the Mucus-aqueous Tear Film LayerTime frame: over 4 hours following instillation of NOV03
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 101
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.